1. Home
  2. STTK vs VSAT Comparison

STTK vs VSAT Comparison

Compare STTK & VSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.91

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Logo ViaSat Inc.

VSAT

ViaSat Inc.

HOLD

Current Price

$48.80

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
VSAT
Founded
2016
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
5.6B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
STTK
VSAT
Price
$3.91
$48.80
Analyst Decision
Buy
Buy
Analyst Count
7
6
Target Price
$6.20
$43.60
AVG Volume (30 Days)
683.9K
2.0M
Earning Date
03-26-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$4,616,074,000.00
Revenue This Year
N/A
$5.25
Revenue Next Year
N/A
$3.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.07
52 Week Low
$0.69
$7.36
52 Week High
$4.89
$49.68

Technical Indicators

Market Signals
Indicator
STTK
VSAT
Relative Strength Index (RSI) 51.62 58.00
Support Level $3.76 $43.87
Resistance Level $4.23 $47.98
Average True Range (ATR) 0.30 3.50
MACD -0.04 0.07
Stochastic Oscillator 51.06 75.17

Price Performance

Historical Comparison
STTK
VSAT

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

Share on Social Networks: